Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment (NCT06532773)
🩺 Plain-English Summary (8th-Grade Level)
People with hematologic cancer often have sleep disturbance and symptoms of fatigue, stress, and pain. This study is being done to test a mindfulness intervention for sleep disturbance and symptom management in patients with hematologic cancer during and after inpatient treatment (Nite2Day+). Participants will complete a baseline survey online, using a mobile application, or paper/pencil. Once the baseline survey is complete, participants will be randomized (like a flip of a coin) to receive Nite2Day+ or Standard Care. Nite2Day+ will include activities during and after inpatient treatment. During inpatient treatment, participants will use a mobile app to access: 1) mindfulness meditations, 2) brief sleep education videos, and 3) brief videos teaching strategies to improve sleep quality in the hospital. After inpatient treatment, participants will complete 6, videoconference sessions (45-60 minutes) with a trained therapist to learn mindfulness and behavioral coping strategies to self-manage nighttime sleep disturbance and daytime symptoms of fatigue, stress, and pain. Three follow-up surveys will occur at hospital discharge, and approximately 8, and 12 weeks after hospital discharge. Participants randomized to Nite2Day+ will be given the option to complete an exit interview to provide feedback on the Nite2Day+ program. Participants randomized to Standard Care will only complete the four surveys. All participants will continue to receive their usual medical care. The total study duration is about 16 weeks.
Who can join: Review the eligibility criteria below.
Location: 2400 Pratt Street — Durham, North Carolina
Age range: 18 Years
🧪 Interventions in This Study
- Nite2Day+ (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- 2400 Pratt Street — Durham, North Carolina
📞 Contact the Study Coordinator
Phone: (919) 416-3471
Email: hannah.fisher@duke.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematologic Malignancy
- A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors — Boston, Massachusetts
- Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation — New York, New York
- Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity — Winston-Salem, North Carolina
- Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation — Seattle, Washington
- Critical Care Outcomes of Hematologic Oncology Patients — Calgary, Alberta
- Expressive Writing Program Among Young Adults With Blood Cancer — Washington D.C., District of Columbia
Explore by condition: All Hematologic Malignancy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.